Zidovudine Other names: Azidothymidine

Chemical formula: C₁₀H₁₃N₅O₄  Molecular mass: 267.241 g/mol  PubChem compound: 35370

Therapeutic indications

Zidovudine is indicated for:

Human immunodeficiency virus infection

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Zidovudine is indicated in anti-retroviral combination therapy for Human Immunodeficiency Virus (HIV) infected adults and children.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Chemoprophylaxis in HIV-positive pregnant women

Population group: women, only adults (18 - 65 years old)

Zidovudine chemoprophylaxis is indicated for use in HIV-positive pregnant women (over 14 weeks of gestation) for prevention of maternal-foetal HIV transmission and for primary prophylaxis of HIV infection in newborn infants.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Primary prophylaxis of HIV infection

Population group: only newborns (0 - 40 days old) , infants (40 days - 1 year old)

Zidovudine chemoprophylaxis is indicated for primary prophylaxis of HIV infection in newborn infants.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Zidovudine is contraindicated in the following cases:

Abnormally low neutrophil counts or haemoglobin levels

at least one of
Neutropenia
Hemoglobin low

Newborn infants with hyperbilirubinaemia or with increased transaminase levels

at least one of
Neonatal hyperbilirubinemia
Serum glutamic oxaloacetic transaminase level raised
Alanine aminotransferase above reference range

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: RETROVIR Concentrate for solution for infusion
Summary of Product Characteristics (SPC) 2022: RETROVIR Capsules, hard
Summary of Product Characteristics (SPC) 2022: RETROVIR Oral solution/syrup
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈